An educational symposium sponsored by Sandoz – attend in person or view via live broadcast

Arcotel Kaiserwasser, Wagramer Str. 8, Vienna (Map)
Sunday, 21 October 2018

Register here

Can the introduction of novel Inflammatory Bowel Disease (IBD) assessment tools that provide a measure of overall disease severity change how we manage IBD and improve patient outcomes? Join what promises to be a lively exchange between some of the leading experts in gastroenterology and IBD in this Sandoz-sponsored educational symposium.

Meet the faculty

  • Silvio Danese

    Silvio Danese, MD, PhD is Head of the IBD Research Unit, Division of Gastroenterology at the Humanitas Research Hospital, Rozzano, Milan, Italy.

  • Walter Reinisch

    Walter Reinisch, MD, PhD is Professor at the Department of Internal Medicine III, Division Gastroenterology and Hepatology, Medical University Vienna, Austria.

  • Stefan Schreiber

    Stefan Schreiber, MD, PhD is Professor of Medicine and Gastroenterology at the
    Christian-Albrechts-University in Kiel, Germany.



    Chair: Professor Silvio Danese
    Speakers: Professor Walter Reinisch & Professor Stefan Schreiber

    19:45–20:00 – Arrivals and refreshments

    20:00–20:10 – Welcome from the Chair (S. Danese)

    Our Chair for the evening, Professor Silvio Danese, welcomes you to this educational symposium and outlines the need for improved IBD assessment tools

    20:10–20:50 - Scientific discussion (W. Reinisch & S. Schreiber)

    In what promises to be an engaging and lively debate, Professor Walter Reinisch and Professor Stefan Schreiber will go head-to-head over the use of novel IBD assessment tools in clinical practice

    20:50–21:00 - Audience Q&A (S. Danese)

    Professor Silvio Danese will facilitate a question and answer session

    21:00 – Departures


    The introduction of targeted therapies, such as the anti-TNFα agents, has transformed the management of moderate-to-severe IBD patients. They offer the opportunity to induce and maintain remission, while healing the mucosa and increasing patients’ quality of life. However, disease activity is currently based on an assessment that represents a snapshot in time – not the long-term ongoing burden that comes with constantly fluctuating inflammatory markers. Current assessment tools may not accurately reflect disease severity, potentially delaying treatment modification and affecting short- and long-term patient outcomes.

    Can a new set of IBD assessment tools change this and help herald a new era where medical decisions are based on the overall disease severity and not just the current disease activity? Assessing overall disease severity offers physicians the opportunity to treat beyond symptoms, identify patients that would benefit from early intervention to prevent mucosal damage, and improve patient quality of life.

    In this educational symposium, our expert faculty will discuss the new IBD assessment tools, including the IBD Index, and how they may change clinical practice.

Login/ Register Maximise Minimise

Alternatively login via